M

Mayinglong Pharmaceutical Group Co Ltd
SSE:600993

Watchlist Manager
Mayinglong Pharmaceutical Group Co Ltd
SSE:600993
Watchlist
Price: 28.02 CNY -0.21%
Market Cap: 12.1B CNY
Section:
Wall Street Price Targets
Wall Street Price Targets
Revenue Forecast
Operating Income Forecast
Net Income Forecast
See Also
Price Target
Average
+38%
Revenue
Forecast
+15%
Operating Income
Forecast
+17%
Net Income
Forecast
+18%

Wall Street
Price Targets

Price Targets Summary
Mayinglong Pharmaceutical Group Co Ltd

Wall Street analysts forecast Mayinglong Pharmaceutical Group Co Ltd stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for Mayinglong Pharmaceutical Group Co Ltd is 38.63 CNY with a low forecast of 37.62 CNY and a high forecast of 40.43 CNY.

Lowest Forecast
Wall Street Target
37.62 CNY
34% Upside
Average Forecast
Wall Street Target
38.63 CNY
38% Upside
Highest Forecast
Wall Street Target
40.43 CNY
44% Upside
Lowest
Price Target
37.62 CNY
34% Upside
Average
Price Target
38.63 CNY
38% Upside
Highest
Price Target
40.43 CNY
44% Upside
Mayinglong Pharmaceutical Group Co Ltd Competitors:
Price Targets
VETO
Vetoquinol SA
33% Upside
H
600566
Hubei Jumpcan Pharmaceutical Co Ltd
17% Upside
MVP
Medical Developments International Ltd
48% Upside
T
TORNTPHARM
Torrent Pharmaceuticals Ltd
13% Upside
VETO
Vetoquinol SA
33% Upside
H
600566
Hubei Jumpcan Pharmaceutical Co Ltd
17% Upside
MVP
Medical Developments International Ltd
48% Upside
T
TORNTPHARM
Torrent Pharmaceuticals Ltd
13% Upside
KLBF
Kalbe Farma Tbk PT
11% Upside
688578
Shanghai Allist Pharmaceuticals Co Ltd
11% Upside
185750
Chong Kun Dang Pharmaceutical Corp
52% Upside
G
GLENMARK
Glenmark Pharmaceuticals Ltd
3% Upside

Revenue
Forecast

Revenue Estimate
Mayinglong Pharmaceutical Group Co Ltd

For the last 8 years the compound annual growth rate for Mayinglong Pharmaceutical Group Co Ltd's revenue is 7%. The projected CAGR for the next 3 years is 15%.

7%
Past Growth
15%
Estimated Growth
Estimates Accuracy
1%
Average Beat
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Mayinglong Pharmaceutical Group Co Ltd

For the last 8 years the compound annual growth rate for Mayinglong Pharmaceutical Group Co Ltd's operating income is 13%. The projected CAGR for the next 3 years is 17%.

13%
Past Growth
17%
Estimated Growth
Estimates Accuracy
3%
Average Beat
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Mayinglong Pharmaceutical Group Co Ltd

For the last 8 years the compound annual growth rate for Mayinglong Pharmaceutical Group Co Ltd's net income is 10%. The projected CAGR for the next 3 years is 18%.

10%
Past Growth
18%
Estimated Growth
Estimates Accuracy
-6%
Average Miss
What are analyst estimates?

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is Mayinglong Pharmaceutical Group Co Ltd's stock price target?
Price Target
38.63 CNY

According to Wall Street analysts, the average 1-year price target for Mayinglong Pharmaceutical Group Co Ltd is 38.63 CNY with a low forecast of 37.62 CNY and a high forecast of 40.43 CNY.

What is Mayinglong Pharmaceutical Group Co Ltd's Revenue forecast?
Projected CAGR
15%

For the last 8 years the compound annual growth rate for Mayinglong Pharmaceutical Group Co Ltd's revenue is 7%. The projected CAGR for the next 3 years is 15%.

What is Mayinglong Pharmaceutical Group Co Ltd's Operating Income forecast?
Projected CAGR
17%

For the last 8 years the compound annual growth rate for Mayinglong Pharmaceutical Group Co Ltd's operating income is 13%. The projected CAGR for the next 3 years is 17%.

What is Mayinglong Pharmaceutical Group Co Ltd's Net Income forecast?
Projected CAGR
18%

For the last 8 years the compound annual growth rate for Mayinglong Pharmaceutical Group Co Ltd's net income is 10%. The projected CAGR for the next 3 years is 18%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 262,500+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.